Oral Corticosteroid Relieves Post-COVID-19 Anosmia in a 35-Year-Old Patient

Case Reports in ENT
13 Jan, 2021 ,

Sam K. Touisserkani et.al. presented a case of a 35-year-old woman who presented with anosmia after recovery from COVID-19. In many cases, this chemosensitive dysfunction persisted after the negativization of the nasopharyngeal swab. The researchers report effective treatment of anosmia by oral corticosteroid therapy in a patient recovered from COVID-19.

Full content

A 35-year-old woman presented with anosmia after recovery from COVID-19. About two weeks before the anosmia, she had experienced low-grade fever, dry coughing, and headache. Due to the outbreak of COVID-19, physicians evaluated her for SARS-CoV-2 paraclinical examinations.

Her lab test revealed positive CRP (3+) and lymphopenia. Chest CT scan showed patchy ground-glass and peripheral infiltration. A throat swab sample was taken, and reverse real-time PCR assay confirmed SARS-CoV-2 infection.

She was referred to an otolaryngologist for her anosmia. A complete head and neck examination was performed. The nasal cavity, oral cavity, and cranial nerve functions (II–V, VII–IX, and XII) were normal. The patient was diagnosed with postviral olfactory dysfunction. Rhinocort spray, one puff BID for 10 days, was prescribed for her.

However, no improvement was observed. A throat swab sample was taken, and reverse real-time PCR was performed again. The second PCR result was negative. Oral prednisolone was prescribed. After 6 days of consuming prednisolone, her anosmia reversed.